Enstilar® - the First Combination Foam Spray for Psoriasis Launches in the UK

HURLEY, England, July 13, 2016 /PRNewswire/ --

FOR DISTRIBUTION TO UK CONSUMER MEDIA ONLY (EXCLUDING REPUBLIC OF IRELAND AND MEDICAL MEDIA)

The fixed-combination foam spray (calcipotriol/betamethasone dipropionate 50 micrograms/g + 0.5 mg/g) is more effective than other combination treatments for all severities of plaque psoriasis in adults  

People in the UK living with psoriasis now have a new treatment option with which to manage their condition. Enstilar^® is the first psoriasis treatment available in a foam spray formulation for application to the skin, for use in adults.^[1] It is available on prescription only. The launch of Enstilar^® provides GPs and dermatology healthcare professionals with a new solution to support people living with psoriasis by helping them to regain control and live well with this chronic, life-impacting skin condition.

The clinical data shows that it is a more effective topical combination treatment than those currently available and is generally well-tolerated.^[2],[3] Additionally, in clinical trials, more than half of patients experienced significant visible signs of improvement after four weeks, and with some patients seeing improvements at one week.^[4]

"The launch of Enstilar® foam spray in the UK is a significant advance which provides an easy to apply topical combination treatment for plaque psoriasis, a distressing condition which affects up to 2 million people in this country.  The fact that Enstilar® is more effective than other topical combination treatments and is generally well-tolerated means that individuals with psoriasis now have the chance to discuss with their GP or dermatologist whether this once-daily, foam spray may be an option that they should consider," commented Dr Keith Freeman, Consultant Dermatologist, Sunderland.

The delivery system of the new foam spray provides a convenient treatment option for psoriasis patients,^[2] ensuring the product is easy-to-apply.^[2] It was developed to treat patients with plaque psoriasis^[1] - the most common clinical form of psoriasis, affecting approximately 80% of psoriasis patients.^[5]

Impact on Quality of Life 

This treatment can also improve patients' quality of life (QoL).^[6] 75% of patients feel that their quality of life is significantly impacted by psoriasis, both emotionally and physically.^[6] 81% of psoriasis patients using Enstilar^® foam spray in trials reported QoL improvements after four weeks,^[7] with more than 70% seeing a reduction in itch-related sleep loss.^[4] The symptomatic relief experienced by the majority of patients may be attributed to the cooling effect of the new foam spray.^[8]